What is Serimmune?
At its core, Serimmune specializes in the sophisticated mapping of human antibody reactomes. The company provides a high-throughput short epitope profiling and discovery platform that serves as a critical tool for biomarker identification and translational science. By facilitating a deeper understanding of immune system dynamics, the organization enables researchers to accelerate drug development and diagnostic innovation. Following its integration with Infinity Bio, Inc., the company has significantly expanded its technological footprint, leveraging advanced computational resources to maintain its competitive edge in the rapidly evolving field of immunology research.
How much funding has Serimmune raised?
Serimmune has raised a total of $10.5M across 2 funding rounds:
Private Equity
$2.5M
Private Equity
$8M
Private Equity (2016): $2.5M, investors not publicly disclosed
Private Equity (2017): $8M led by Illumina Ventures and Merck
Key Investors in Serimmune
Illumina Ventures
Illumina Ventures is a leader in genomics and precision health investing, focused on building an ecosystem that translates investment into innovation to enhance human health.
Merck
Founded in 1891 and headquartered in Rahway, NJ, Merck & Co., Inc. is a global healthcare company delivering innovative solutions through prescription medicines, biologic therapies, vaccines, and animal health products.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Serimmune?
With the backing of major strategic partners, the company is well-positioned to scale its antibody reactome services and deepen its impact on precision medicine. The current lifecycle stage, characterized by major enterprise-level funding, suggests a shift toward commercial expansion and the broad application of its discovery platform across pharmaceutical and clinical research pipelines. Future growth will likely focus on enhancing the scalability of its epitope profiling technology, ensuring that the firm remains at the forefront of immune intelligence while driving significant advancements in therapeutic discovery and patient-centric healthcare solutions.
See full Serimmune company page
